TIL
Instil Bio, Inc. [TIL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TIL Stock Summary
Top 10 Correlated ETFs
TIL
Top 10 Correlated Stocks
TIL
In the News
TIL Financial details
Company Rating
Neutral
Market Cap
70.86M
Income
-155.35M
Revenue
0
Book val./share
34.72
Cash/share
23.35
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-5.1
Forward P/E
-
PEG
1.66
P/S
-
P/B
4.28
P/C
0.46
P/FCF
-0.36
Quick Ratio
13.62
Current Ratio
14.53
Debt / Equity
0.37
LT Debt / Equity
-
-
-
EPS (TTM)
-23.89
EPS next Y
-
EPS next Q
-
EPS this Y
-30.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-80.81%
-
-
-
-
SMA20
-8.33%
SMA50
-8.33%
SMA100
57.14%
Inst Own
55.9%
Inst Trans
0.89%
ROA
-58%
ROE
-65%
ROC
-0.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.08-14.0
52W High
-23.71%
52W Low
+78%
RSI
41
Rel Volume
0.34
Avg Volume
27.45K
Volume
9.34K
Perf Week
-3.44%
Perf Month
-10.78%
Perf Quarter
48.33%
Perf Half Y
40.53%
-
-
-
-
Beta
1.252
-
-
Volatility
0.18%, 0.68%
Prev Close
2.59%
Price
10.68
Change
3.29%
TIL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.02 | 0 | 0 | 0 | |
| Net income per share | -1.01 | -5.89 | -24.3 | -34.46 | -24 | |
| Operating cash flow per share | -0.83 | -4.62 | -18.93 | -27.82 | -12.61 | |
| Free cash flow per share | -0.94 | -12.55 | -27.9 | -40.88 | -15.79 | |
| Cash per share | 1.39 | 37.71 | 70.39 | 40.29 | 23.35 | |
| Book value per share | -1.08 | -6.18 | 86.06 | 56.15 | 34.72 | |
| Tangible book value per share | -1.08 | -8.65 | 83.61 | 56.15 | 34.72 | |
| Share holders equity per share | -1.08 | -6.18 | 86.06 | 56.15 | 34.72 | |
| Interest debt per share | 0 | 0 | 0 | 12.63 | 13.59 | |
| Market cap | 3.39B | 3.39B | 2.21B | 81.59M | 49.56M | |
| Enterprise value | 3.38B | 3.15B | 2.17B | 117.78M | 124.92M | |
| P/E ratio | -525.25 | -89.83 | -14.08 | -0.37 | -0.32 | |
| Price to sales ratio | 0 | 24.56K | 0 | 0 | 0 | |
| POCF ratio | -640.46 | -114.46 | -18.08 | -0.45 | -0.6 | |
| PFCF ratio | -560.04 | -42.15 | -12.27 | -0.31 | -0.48 | |
| P/B Ratio | -491.86 | -85.61 | 3.98 | 0.22 | 0.22 | |
| PTB ratio | -491.86 | -85.61 | 3.98 | 0.22 | 0.22 | |
| EV to sales | 0 | 22.81K | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -515.01 | -92.51 | -13.95 | -0.59 | -1.46 | |
| EV to operating cash flow | -638.78 | -106.3 | -17.77 | -0.65 | -1.52 | |
| EV to free cash flow | -558.57 | -39.14 | -12.06 | -0.44 | -1.22 | |
| Earnings yield | 0 | -0.01 | -0.07 | -2.74 | -3.15 | |
| Free cash flow yield | 0 | -0.02 | -0.08 | -3.24 | -2.07 | |
| Debt to equity | 0 | 0 | 0 | 0.22 | 0.37 | |
| Debt to assets | 0 | 0 | 0 | 0.17 | 0.26 | |
| Net debt to EBITDA | 1.35 | 7.1 | 0.24 | -0.18 | -0.88 | |
| Current ratio | 6.54 | 18.53 | 11.22 | 8.22 | 15.22 | |
| Interest coverage | 0 | 0 | 0 | -120.26 | -17.38 | |
| Income quality | 0.81 | 0.78 | 0.78 | 0.81 | 0.53 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 104.22 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 140.57 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.05 | 0.03 | 0 | 0 | |
| Capex to operating cash flow | 0.14 | 1.72 | 0.47 | 0.47 | 0.25 | |
| Capex to revenue | 0 | -368.23 | 0 | 0 | 0 | |
| Capex to depreciation | -38 | -198.5 | -21.01 | -14.13 | -4.34 | |
| Stock based compensation to revenue | 0 | 12.36 | 0 | 0 | 0 | |
| Graham number | 4.93 | 28.6 | 216.93 | 208.66 | 136.93 | |
| ROIC | 0.95 | 0.85 | -0.28 | -0.5 | -0.29 | |
| Return on tangible assets | -0.68 | -0.12 | -0.26 | -0.46 | -0.48 | |
| Graham Net | -1.17 | -17.77 | 61.9 | 21.99 | 8 | |
| Working capital | 7.87M | 232.86M | 422.66M | 236.59M | 150.2M | |
| Tangible asset value | -6.89M | -55.43M | 539.37M | 363.61M | 225.83M | |
| Net current asset value | -7.08M | -112.47M | 409.24M | 150.86M | 60.96M | |
| Invested capital | 0 | 0 | 0 | 0.22 | 0.37 | |
| Average receivables | 0 | 1.59M | 1.59M | 0 | 0 | |
| Average payables | 0 | 2.24M | 4.53M | 3.96M | 1.79M | |
| Average inventory | 0 | 590.5K | 590.5K | 0 | 0 | |
| Days sales outstanding | 0 | 8.39K | 0 | 0 | 0 | |
| Days payables outstanding | 17.87K | 0 | 738.49 | 143.82 | 93.02 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0.04 | 0 | 0 | 0 | |
| Payables turnover | 0.02 | 0 | 0.49 | 2.54 | 3.92 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.94 | 0.95 | -0.28 | -0.61 | -0.69 | |
| Capex per share | -0.12 | -7.93 | -8.96 | -13.06 | -3.18 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -8.29 | -8.66 | -2.87 | -10.37 | -1.99 | |
| Operating cash flow per share | -5.69 | -5.33 | -3.01 | -2.22 | -2.06 | |
| Free cash flow per share | -7.7 | -6.63 | -4.08 | -3.01 | -2.07 | |
| Cash per share | 40.18 | 34.32 | 31.01 | 28.21 | 23.35 | |
| Book value per share | 55.99 | 47.84 | 45.59 | 35.98 | 34.72 | |
| Tangible book value per share | 55.99 | 47.84 | 45.59 | 35.98 | 34.72 | |
| Share holders equity per share | 55.99 | 47.84 | 45.59 | 35.98 | 34.72 | |
| Interest debt per share | 12.42 | 12.91 | 13.48 | 12.95 | 13.09 | |
| Market cap | 81.82M | 85.96M | 71.67M | 55.67M | 49.56M | |
| Enterprise value | 118.01M | 141.96M | 137.01M | 132.8M | 124.92M | |
| P/E ratio | -0.38 | -0.38 | -0.96 | -0.21 | -0.96 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -2.21 | -2.48 | -3.66 | -3.86 | -3.7 | |
| PFCF ratio | -1.64 | -1.99 | -2.7 | -2.84 | -3.69 | |
| P/B Ratio | 0.23 | 0.28 | 0.24 | 0.24 | 0.22 | |
| PTB ratio | 0.23 | 0.28 | 0.24 | 0.24 | 0.22 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -3.86 | -4.72 | -8.03 | -1.99 | -10.57 | |
| EV to operating cash flow | -3.19 | -4.1 | -7 | -9.21 | -9.34 | |
| EV to free cash flow | -2.36 | -3.29 | -5.16 | -6.78 | -9.3 | |
| Earnings yield | -0.66 | -0.66 | -0.26 | -1.21 | -0.26 | |
| Free cash flow yield | -0.61 | -0.5 | -0.37 | -0.35 | -0.27 | |
| Debt to equity | 0.22 | 0.27 | 0.29 | 0.37 | 0.37 | |
| Debt to assets | 0.17 | 0.2 | 0.21 | 0.25 | 0.26 | |
| Net debt to EBITDA | -1.18 | -1.86 | -3.83 | -1.16 | -6.38 | |
| Current ratio | 8.22 | 9 | 12 | 14.53 | 15.22 | |
| Interest coverage | -76.24 | -91.9 | -35.57 | 33.31 | -6.49 | |
| Income quality | 0.69 | 0.61 | 1.05 | 0.21 | 1.04 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.35 | 0.24 | 0.36 | 0.36 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -6.2 | -4.77 | -7.04 | -5.41 | -0.06 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 102.21 | 96.55 | 54.25 | 91.62 | 39.4 | |
| ROIC | -0.12 | -0.14 | -0.05 | -0.2 | -0.04 | |
| Return on tangible assets | -0.11 | -0.13 | -0.05 | -0.2 | -0.04 | |
| Graham Net | 21.93 | 16.48 | 13.82 | 11.87 | 8 | |
| Working capital | 236.59M | 213.43M | 202.21M | 182.16M | 150.2M | |
| Tangible asset value | 363.61M | 311.15M | 296.52M | 234.02M | 225.83M | |
| Net current asset value | 150.86M | 124.1M | 108.79M | 89.38M | 60.96M | |
| Invested capital | 0.22 | 0.27 | 0.29 | 0.37 | 0.37 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 3.84M | 1.85M | 1.75M | 1.9M | 1.43M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 263.09 | 59.31 | 232.81 | 155.35 | 105.29 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.34 | 1.52 | 0.39 | 0.58 | 0.85 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.15 | -0.18 | -0.06 | -0.29 | -0.06 | |
| Capex per share | -2 | -1.3 | -1.07 | -0.79 | -0.01 |
TIL Frequently Asked Questions
What is Instil Bio, Inc. stock symbol ?
Instil Bio, Inc. is a US stock , located in Dallas of Tx and trading under the symbol TIL
What is Instil Bio, Inc. stock quote today ?
Instil Bio, Inc. stock price is $10.68 today.
Is Instil Bio, Inc. stock public?
Yes, Instil Bio, Inc. is a publicly traded company.
Company Profile
- Volume Average 27.45K
- Market Capitalization 70.86M
- Employee 49
- CEO Mr. Bronson Crouch
- Headquarters Dallas,TX,US
- IPO Date 2021-03-19
-
Website
https://instilbio.com 
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
